12 recruiting. 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Recruiting 12 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®) - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH) | Phase 3 | Recruiting | YS Life Science Co., Ltd. | 600 | 2026-06-02 | 2026-09-23 |
| Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure - Glaucoma | Phase 3 | Recruiting | Glaukos Corporation | 510 | 2026-02-17 | 2026-03-30 |
| Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension HUC3-637, HUC3-637-R - Primary Open Angle Glaucoma (POAG), Ocular Hypertension | Phase 3 | Recruiting | Huons Co., Ltd. | 206 | 2026-01-01 | 2026-01-13 |
| [KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension TFC-003, TFC-003-R1, TFC-003-R2+TFC-003-R3 - Glaucoma Open-Angle Primary, Ocular Hypertension | Phase 3 | Recruiting | Kukje Pharma | 188 | 2025-12-09 | 2026-06-23 |
| Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5% - Cataract, Glaucoma | Phase 3 | Recruiting | SpyGlass Pharma, Inc. | 400 | 2025-10-28 | 2025-10-20 |
| Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5% - Cataract, Glaucoma | Phase 3 | Recruiting | SpyGlass Pharma, Inc. | 400 | 2025-10-15 | 2025-10-20 |
| A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma XEN63 Glaucoma Treatment System - Primary Open Angle Glaucoma | Phase 3 | Recruiting | AbbVie | 130 | 2025-02-11 | 2026-10-09 |
| Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial Nicotinomide, Matching placebo - Glaucoma, Open-Angle | Phase 3 | Recruiting | University College, London | 496 | 2024-01-18 | 2024-05-09 |
| Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma Citicoline eye drops 2%, Placebo - Glaucoma, Open-Angle | Phase 3 | Recruiting | Omikron Italia S.r.l. | 1000 | 2023-12-11 | 2024-03-12 |
| Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Recruiting | Amneal Pharmaceuticals, LLC | 168 | 2022-06-29 | 2022-08-10 |
| Clarifying the Optimal Application of SLT Therapy Trial Low Energy SLT, Standard Energy SLT - Glaucoma and Ocular Hypertension | Phase 3 | Recruiting | University of Pittsburgh | 790 | 2021-09-07 | 2026-08-14 |
| Pilocarpine Use After Kahook Goniotomy Pilocarpine, Prednisolone, Ofloxacin - Glaucoma | Phase 3 | Recruiting | Montefiore Medical Center | 142 | 2019-05-01 | 2025-11-10 |
Glaucoma, Open-Angle (8) · Ocular Hypertension (8) · Cataract (3)
Eye Diseases (12) · Ocular Hypertension (4) · Lens Diseases (3)
Bimatoprost (2) · Ofloxacin (1) · Ophthalmic Solutions (1) · Pilocarpine (1) · Prednisolone (1) · prednisolone acetate (1)
SpyGlass Pharma, Inc. (2) · AbbVie (1) · Amneal Pharmaceuticals, LLC (1) · Glaukos Corporation (1) · Huons Co., Ltd. (1) · Kukje Pharma (1) · Montefiore Medical Center (1) · Omikron Italia S.r.l. (1) · University College, London (1) · University of Pittsburgh (1) · YS Life Science Co., Ltd. (1)
United States (8) · South Korea (2) · Canada (1) · India (1) · Italy (1) · United Kingdom (1)
Paul Yoo, OD (2) · David Garway-Heath (1) · Goundappa K Balasubramani, PhD (1) · Stephen Wisniewski, PhD (1) · Tony Realini, MD, MPH (1)
2UG1EY031651-06 (1), UG1EY031651 (1)